MediWound Ltd.
MDWDMediWound Ltd. is an Israel-based biopharmaceutical company specializing in the development and commercialization of innovative therapies for burned and wounded skin, including its flagship product, NexoBrid, a new biological enzyme designed for the removal of eschar in burn patients. The company's technologies focus on tissue repair, wound care, and bio-surgical solutions.
Company News
The chronic venous insufficiency market is projected to grow from $2.1 billion in 2024 to a larger market by 2034, driven by emerging therapies, medical devices, and increasing prevalence of the condition in aging populations.
MediWound reported a 43% quarterly revenue increase to $5.7 million, improved gross margins, and advanced its Phase III EscharEx trial while establishing strategic partnerships with wound care leaders.
MediWound has initiated a global Phase III trial to evaluate the efficacy and safety of its wound debridement therapy EscharEx for the treatment of venous leg ulcers. The trial aims to assess EscharEx's ability to effectively debride chronic wounds and prepare the wound bed for healing.
MediWound Ltd. has received a €16.25 million grant from the European Innovation Council, which is expected to accelerate the development of its product EscharEx for Diabetic Foot Ulcers. TD Cowen has maintained a Buy rating on MediWound's stock with a $25.00 price target.
MediWound Ltd. has been awarded €16.25 million in funding from the European Innovation Council to accelerate the development of its EscharEx® product for treating diabetic foot ulcers, which could significantly impact the lives of millions of patients.
